HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effectiveness of the direct renin inhibitor, aliskiren, in patients with resistant hypertension.

Abstract
Currently there is no consensus regarding which add-on therapy to use in resistant hypertension. We have conducted an open observational study of the use of aliskiren in resistant hypertensive patients. Forty-three patients with resistant hypertension were included in the study. The inclusion criteria were as follows: 1) office blood pressure (BP) > 140/90 mmHg despite treatment with at least three or more antihypertensive drugs; 2) no prior therapy with aliskiren; and 3) no renal insufficiency. Follow-up BP was determined at 1 and 3 months. Baseline BP was 153 ± 12/79 ± 12 mmHg. After 3 months, systolic BP (SBP) and diastolic BP (DBP) dropped significantly: 140 ± 19/73 ± 13 mmHg (P < 0.0001). Twenty-one patients (49%) had an office BP < 140/90 mmHg, and these patients were assigned to the good BP control group. Another 22 were placed into the poor BP control group. BP reductions from baseline in the good BP control group (SBP/ DBP: 19 ± 11/8 ± 7 mmHg) were larger than those in the poor BP control group (5 ± 15/3 ± 9 mmHg, P < 0.05). Mean BP (MBP) values at baseline, 1, and 3 months were higher in the poor BP control group. There was no significant difference in pulse pressure at baseline between the 2 groups. In multivariate analysis, only MBP at baseline correlated with lack of BP control. Aliskiren administration to resistant hypertensive patients was effective in reducing BP. The present findings suggest aliskiren may be useful as a fourth-line or fifth-line treatment added to other drugs in the treatment of resistant hypertension.
AuthorsYuji Yoshitomi, Ken-ichi Kawanishi, Akihisa Yamaguchi, Shun-ichiro Sakurai, Kazuo Minai, Toshikazu Ishii, Yasuhiro Tarutani, Takashi Tsujibayashi, Masashi Kaneki, Yuichi Saitou, Satoru Suwa
JournalInternational heart journal (Int Heart J) Vol. 54 Issue 2 Pg. 88-92 ( 2013) ISSN: 1349-3299 [Electronic] Japan
PMID23676368 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Amides
  • Antihypertensive Agents
  • Fumarates
  • aliskiren
  • Renin
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Amides (pharmacology, therapeutic use)
  • Antihypertensive Agents (pharmacology, therapeutic use)
  • Female
  • Fumarates (pharmacology, therapeutic use)
  • Humans
  • Hypertension (drug therapy)
  • Logistic Models
  • Male
  • Middle Aged
  • Renin (antagonists & inhibitors)
  • Salvage Therapy
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: